AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Humira (adalimumab) by Quarter
Humira (adalimumab) — Worldwide reported growth YoY (%) (%)
AbbVie Humira (adalimumab): -35.9% in Q2 2026, up 22.2 pts from a year earlier.
Latest, Q2 2026
-35.9%
Period ended Jun 30, 2026
Change on a year earlier
+22.2 pts
-58.1% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Humira | 425 | 331 | 756 | (47.0) | (12.5) | (35.9) | (13.2) | (36.1)”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Humira (adalimumab) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/humira-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.